ADVA
14.4.2022 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today extended its Ensemble Sync Director GNSS assurance software to integrate any third-party vendor’s GNSS receiver observables at scale. A key pillar of ADVA’s aPNT+™ technology, Ensemble Sync Director is now vendor-agnostic, providing defense-in-depth, resilient and assured PNT for more customers than ever before. Ensemble Sync Director can now transparently show and analyze GNSS observables from third-party receivers in even the largest deployments. This is key as synchronization based on satellite signals is vulnerable to failure, interference and cyberthreats, and so network operators urgently need to protect their critical timing with continuous monitoring and assurance. Now, they have the power to remotely detect issues with GNSS receivers from any vendor, helping to maintain high-quality timing performance, avoid disruptions and reduce operating costs.
“The number of GNSS devices in use is growing by the day, with many networks now relying on hundreds or even thousands of receivers. At the same time, the risks to satellite-based timing have never been greater, including the rising threat of jamming and spoofing attacks. By extending our GNSS assurance application capabilities beyond our own timing equipment, we’re empowering many more customers to protect their mission-critical synchronization in new or deployed infrastructure,” said Gil Biran, GM of Oscilloquartz, ADVA. “Our Ensemble Sync Director, with comprehensive GNSS assurance for both resilient and assured PNT, provides a simple, scalable and highly cost-efficient way to harness our unique experience and expertise in managing a huge number of GNSS-dependent network elements.”
ADVA’s Oscilloquartz GNSS assurance solution for integrating third-party receiver data is an extension of its Sync Director application, part of the Ensemble Controller network management platform. It offers centralized in-service monitoring and analysis of GNSS status and reliability as well as AI/ML-based prediction and prevention of obstruction, jamming and spoofing. Using topology and timing chain mapping, Ensemble Sync Director displays the entire timing network infrastructure in a user-intuitive graphical format. ADVA’s GNSS assurance capabilities are aligned with the goals of the DHS Resilient PNT Conformance Framework and future IEEE P1952 Resilient PNT Standard to protect critical infrastructure. Available from ADVA Professional Services, the new solution is ideal for network operators in telecoms, power utilities, financial trading, data centers and more, who need to ensure robust, reliable and resilient GNSS timing. It also offers significant value to system integrator vendors looking to add vital GNSS protection capabilities to their synchronization portfolio.
“People are increasingly aware of the risk factors affecting GNSS-reliant systems, as well as the heavy price that disruption can bring. Whether they are addressing PNT regulations or responding to the precarious geopolitical situation, more and more network operators are looking to take urgent action to safeguard their timing architectures with resilient and assured PNT capabilities. That’s why we’re extending our GNSS assurance software with real-time monitoring to integrate third-party timing receiver data and enable more customers to proactively protect their critical infrastructure,” commented Michael Port, VP of product line management at ADVA. “Scalable and easy to implement, our new offering adds instant value. What’s more, Ensemble Sync Director supports open integration, enabling end-to-end vendor-agnostic sync and timing network management.”
Further information is available in these slides: https://adva.li/third-party-gnss-assurance-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005726/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
